David Rosen Comments on FDA, Compounder Conflict Over Drug Shortages
June 6, 2025
BioSpace
Foley & Lardner LLP partner David Rosen highlighted the U.S. Food and Drug Administration’s drug shortage list in the BioSpace article, “Post-Chevron Legal Battles: Three Key Cases to Watch.”
“Up until very recently, no one cared if a drug came on or off the drug shortage list,” Rosen explained. “If anything, the reaction was, ‘Okay, it’s off shortage, everybody’s happy.’ That was until what happened with the GLP-1s.”
Rosen added that though the FDA previously had deference from the courts to determine shortages, this process was neither well codified or clearly in the public domain.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."